Climb Bio, Inc. CLYM
11.66
(0.23)
(1.93%)
as of 25 Sep
- Market cap
- $682.9M
- P/E
- 0.0×
Follow CLYM
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
31.45 | 27.86 | 15.16 | 18.38 |
+8 more quarters Free account |
Net Debt/EBITDA |
11.66 | 7.08 | 5.11 | 5.65 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 1.05 | 0.89 | 0.94 | |
Capex/Depreciation |
0.74 | 0.00 | 0.00 | 0.22 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.14) | (0.21) | (0.23) | (0.18) | |
Cash per Share |
2.40 | 1.61 | 1.49 | 1.28 | |
Shareholders Equity per Share |
3.15 | 2.17 | 2.37 | 2.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.15 | 2.17 | 2.37 | 2.60 | |
Free Cash Flow |
(10.81) | (14.38) | (15.63) | (12.25) | |
Working Capital |
180.70 | 109.33 | 98.87 | 86.02 | |
Capital Expenditures |
(0.26) | — | 0.00 | (0.11) | |
Net Current Asset Value |
179.89 | 109.12 | 98.58 | 85.66 | |
| Other line items | |||||
Quick Ratio |
30.86 | 26.91 | 14.47 | 17.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.21) | (0.23) | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.04 | 0.82 | 1.49 | 0.38 | |
Average Assets |
219.34 | 176.56 | 192.47 | 202.25 | |
Average Common Equity |
212.66 | 170.74 | 186.18 | 197.89 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates